---
authors:
- admin
bio: My research interests include neuropathology, proteomics, transcriptomics and biomarker discovery. 
education:
  courses:
  - course: D.Phil/PhD in Clinical Neurosciences
    institution: University of Oxford
    year: 2021
  - course: BSc (Hons) in Biomedical Sciences
    institution: University of Greenwich
    year: 2012

email: "connor.david.scott@gmail.com"
interests:
- Drug Discovery / Drug Development
- Cell Biology / Molecular Biology
- Histology / Neuropathology
- Neurodegeneration / Psychiatry
- Proteomics / Transciptomics 
name: Connor Scott
organizations:
- name: Alkermes
  url: "https://www.alkermes.com"
- name: Nuffield Department of Clinical Neurosciences
  url: "https://www.ndcn.ox.ac.uk/" 
role: Scientist (Alkermes) / Honorary Research Fellow (Oxford)
social:
- icon: researchgate
  icon_pack: fab
  link: https://www.researchgate.net/profile/Connor_Scott4
- icon: google-scholar
  icon_pack: ai
  link: https://scholar.google.com/citations?user=Sr2q5WYAAAAJ&hl=en
superuser: true
user_groups:
- Researchers
- Visitors
--- 

Connor Scott is an experienced neuroscientist with over 12 years of expertise in <b>ex vivo research</b>, specialising in the analysis of human and rodent tissue, histology, molecular biology, and mass spectrometry.

Throughout his career, Connor has been dedicated to advancing our understanding of the <b>molecular mechanisms underlying neurodegenerative and psychiatric disorders</b>. His work spans cutting-edge research initiatives and innovative drug discovery programs aimed at uncovering novel therapeutic solutions.

Connor is a recognised <b>subject matter expert</b> in:
<br>
<br>
<div style="display: flex; justify-content: center; align-items: center;">
    <img src="/img/ex-vivo.png" alt="Connor’s Research Overview" style="width:650px; height:auto;">
</div>
<br>

Connor’s research encompasses some of the most challenging and impactful areas of neuroscience, including neurodegenerative conditions such as <b>Alzheimer's disease</b>, <b>frontotemporal dementia</b>, and <b>amyotrophic lateral sclerosis (ALS)</b>. He also brings significant expertise to psychiatric disorders like <b>schizophrenia</b> and complex diseases with neurological components such as <b>narcolepsy</b> and <b>glioblastoma multiforme</b>.

With a passion for advancing neuroscience and a track record of impactful contributions, Connor continues to drive innovation at the intersection of research and drug discovery.

<i>Scroll down to see a overview of his professional contributions or click on the headings above to see a detailed overview.</I>
